Novartis AG's out-going CEO Joe Jimenez said the revamped diversified Swiss group is running smoothly, with growth fueled in the third quarter by new therapies and improved performances by generics division Sandoz and its Alcon unit.
Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession
Novartis beat third-quarter forecasts, flagged its strengthening drug portfolio, and said its CEO transition remains on track for February 2018, but a decision on its eye care division awaits.
More from Earnings
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.